Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively ...

Initial uptake of bispecific antibodies for multiple myeloma is promising, especially for Black patients, aligning with disease prevalence. Further data on social determinants and insurance status are ...

New and more advanced treatments are helping people with multiple myeloma live longer. But the outlook hasn't improved at the same pace for everyone with this blood cancer. Black people with multiple ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies. Bispecific therapy, tackling the ...